Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma

Inclusion Criteria:

1. Age ≥ 16 years.
2. Ability to provide written informed consent prior to participating in the trial andany trial related procedures being performed.
3. Ovarian, fallopian tube or primary peritoneal carcinoma of high-grade serous,high-grade (grade 3) endometrioid or carcinosarcoma histologies.
4. Patients with ovarian, fallopian tube or primary peritoneal carcinoma of anyhistological subtype in patients with known germline mutations in BRCA1 or BRCA2.
5. Willingness to comply with scheduled visits, treatment plans, laboratory tests andother trial procedures.
6. Life expectancy > 6 months.
7. No contraindication to obtaining a surgical or image-guided biopsy.
8. Patients with confirmed ovarian, fallopian tube or primary peritoneal carcinoma ofhigh-grade serous, high-grade (grade 3) endometrioid or carcinosarcoma histologies whohave consented for their tissue to be collected under a generic tissue consent (i.e.have not consented to Part 1) may be eligible for full consent following discussionwith the trials team.

Exclusion Criteria:

1. Ovarian, primary peritoneal or fallopian tube cancer of low grade serous, grades 1 or 2 endometrioid or clear cell subtypes unless associated with known germline mutationin BRCA1 or BRCA2
2. Borderline/low malignant potential tumours
3. Any non-epithelial ovarian malignancy
4. Diagnosis of high-grade serous cancer made on cytology only
5. Patients who have received any prior treatment for known high-grade ovarian carcinoma
6. Other severe or uncontrolled systemic disease or evidence of any other significantdisorder or lab finding that makes it undesirable for the patient to participate inthe trial
7. History of physical or psychiatric disorder that would prevent informed consent andcompliance with protocol
8. Pregnant or lactating women
9. Patients with any other severe concurrent disease which may increase the riskassociated with trial participation
10. Any psychological, familial, sociological or geographical consideration potentiallyhampering compliance with the trial protocol and follow up schedule.